#USA #San Diego #Robbins LLP #SEC Lawsuit #Unicycive Therapeutics

Legal Action Against Unicycive Therapeutics: What You Need to Know

On September 8, 2026, Robbins LLP, a law firm dedicated to protecting shareholder rights, highlighted the initiation of a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The lawsuit affects individuals and entities that acquired UNCY securities between December 29, 2025, and June 29, 2026. Unicycive is currently recognized as a clinical-stage biotechnology firm that focuses on developing treatments for kidney diseases.

Allegations Against Unicycive

The complaint outlines serious allegations regarding Unicycive's handling of its New Drug Application (NDA) for oxylanthanum carbonate (OLC). Unicycive submitted the NDA to the U.S. Food and Drug Administration (FDA) in September 2024, with the application being officially accepted by the FDA in November of the same year. However, in June 2025, the FDA issued a Complete Response Letter (CRL) identifying deficiencies related to Unicycive's third-party manufacturing vendor. This official notice sparked a series of events that ultimately led to the recent class action.

One of the key allegations stated in the lawsuit is that Unicycive failed to conduct thorough inspections of its third-party vendor's manufacturing facilities. This oversight violated the requirements stipulated by the FDA, which were aimed at correcting previously noted deficiencies. The lawsuit asserts that due to this lapse, Unicycive lacked a solid foundation to claim its vendor had resolved the identified compliance issues.

Events Leading to the Stock Price Drop

The situation escalated on June 30, 2026, when Unicycive made a startling announcement that the FDA had again issued a CRL regarding the resubmitted NDA for OLC. The new CRL reiterated the same deficiencies identified in the prior CRL from June 2025. This announcement resulted in a significant drop in Unicycive's stock price, plummeting by $3.01 per share, or approximately 39.1%, closing at $4.69 on the same day amidst heavy trading activity.

Who Can Join the Class Action?

Eligible participants in the lawsuit are those who purchased or acquired Unicycive Therapeutics securities during the specified class period. If these investors incurred substantial losses, they are encouraged to reach out to Robbins LLP to explore their legal rights under federal securities laws. As part of the lawsuit process, a lead plaintiff will be appointed, representing the interests of all class members throughout the litigation.

Robbins LLP has established a deadline for potential lead plaintiffs to join the lawsuit, which is set for November 2, 2026. Individuals interested in taking on the lead plaintiff role are urged to act promptly.

The Role of Robbins LLP

Robbins LLP has built a reputation as a prominent firm in shareholder rights litigation. They have successfully recovered over $1 billion in value for investors and have represented clients in significant cases regarding securities fraud. The firm's team emphasizes the principle that companies must provide complete and accurate information to their investors to maintain fair and efficient market conditions.

Contact Information for Potential Claimants

For those interested in learning more about the Unicycive Therapeutics class action lawsuit, Robbins LLP is available for inquiries. Investors can submit their questions via email, reach out to attorney Aaron Dumas, Jr., or call the firm directly at (800) 350-6003. All consultations concerning these legal matters are conducted on a contingency fee basis, resulting in no initial costs for participants.

Conclusion

With the legal proceedings underway, investors who have suffered losses due to Unicycive Therapeutics may find themselves eligible to seek recourse. The importance of holding companies accountable for transparency and compliance with regulations cannot be underestimated. If you are affected, it would be prudent to consider your options and consult with professionals in the field.

Stay informed about your rights and participate in protecting your interests.